Upcoming IPOs: Biotech Firms Set to Raise Capital
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 27 2026
0mins
Should l Buy PSUS?
Source: renaissancecapital
- Biotech Fundraising Plans: Neuropsychiatric therapeutics biotech Seaport Therapeutics (SPTX) plans to raise $201 million at a $976 million market cap, with lead programs including GlyphAllo for major depressive disorder and GlyphAgo for generalized anxiety disorder, indicating its potential in the mental health sector.
- Pulmonary Fibrosis Treatment Progress: Pulmonary fibrosis biotech Avalyn Pharma (AVLN) is also set to raise $201 million at a $683 million market cap, with advanced candidates AP01 and AP02 undergoing global Phase 2b trials, with key data expected in mid to late 2027, potentially enhancing its market position.
- Coagulation Disorder R&D: Hemab Therapeutics (COAG) plans to raise $200 million at a $715 million market cap, developing antibody therapies for inherited bleeding and coagulation disorders, with its lead candidate HMB-001 having completed Phase 2 and ready for Phase 3, reflecting strong market demand.
- Mining Company IPO Plans: Exploration-stage Silver Bow Mining (SBMT) is tentatively scheduled to raise $50 million at a $358 million market cap, focusing on silver, zinc, gold, lead, and copper in Montana, and while it has yet to generate revenue, its mineral resource potential is attracting attention.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PSUS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PSUS
Wall Street analysts forecast PSUS stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 42.330
Low
Averages
High
Current: 42.330
Low
Averages
High
No data
About PSUS
Pershing Square USA, Ltd. (the Fund) is a non-diversified, closed-end investment company. It is designed primarily for long-term investors and is not intended to be a trading vehicle. The Fund's investment objective is to preserve capital and seek maximum, long-term capital appreciation commensurate with reasonable risk. The Fund shall seek to achieve its investment objective by investing principally in common stocks that Pershing Square Capital Management, L.P., a Delaware limited partnership (the Adviser), believes exhibit significant valuation discrepancies between current trading prices and intrinsic business (or net asset) value, often with a catalyst for value recognition. The Adviser expects that the substantial majority of the Fund's investment portfolio shall be invested in 12 to 15 core long-term holdings in large-capitalization, investment grade, free-cash-flow-generative North American durable growth companies. The Fund has no operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bruce Herring Acquires 10,000 Shares in Pershing Square USA
- Share Acquisition Details: Bruce Herring's open-market purchase of 10,000 shares of Pershing Square USA, valued at approximately $434,000, reflects his confidence in the company's future prospects.
- Ownership Stake Analysis: Following this transaction, Herring's direct ownership stake in Pershing Square stands at 0.025%, indicating an enhanced influence within the company that could positively impact investor sentiment.
- Transaction Structure Transparency: The acquisition of all 10,000 shares was direct, with no involvement of trusts, family entities, or derivative instruments, ensuring compliance and transparency, which bolsters market trust in Herring.
- Market Performance and Investment Outlook: Despite PSUS's underwhelming debut performance with a closing price of $40.90, below its $50 IPO price, Herring's purchase may attract further investor interest, enhancing market recognition of the fund.
See More
Ackman's New Fund Debuts, Raising $5 Billion
- Successful Debut: Ackman's Pershing Square USA made a successful debut in the U.S. market, raising $5 billion and providing investors with a direct opportunity to invest in his stock picks, reflecting strong market confidence in his investment strategy.
- Return on Investment: With an annualized return of 16.2% since its inception in 2004, Ackman's investment approach makes the new fund an attractive option for investors, although they can also achieve returns by tracking his trades.
- Management Fees and Discounts: Shareholders investing in Pershing Square USA will incur a 2% management fee, and the fund may trade at a discount to its net asset value, adding uncertainty to investments, yet it still has the potential to outperform the market.
- Portfolio Transparency: Ackman intends to deploy the funds raised from the IPO within weeks and will file his first 13F report by mid-August, allowing investors to clearly understand his portfolio, which further enhances interest and trust in the fund.
See More
RPT-BUZZ-US STOCKS WEEKLY: UNDAUNTED
Market Overview: The U.S. stock market has shown resilience despite economic uncertainties, with investors remaining optimistic about future growth.
Sector Performance: Technology and healthcare sectors have outperformed others, driven by strong earnings reports and positive outlooks.
Economic Indicators: Recent economic data suggests a steady recovery, with improvements in employment rates and consumer spending.
Investor Sentiment: Overall investor sentiment remains bullish, with many looking for opportunities in undervalued stocks amidst market fluctuations.
See More
Bill Ackman's Investments Boost PS Stock Price
- Stock Price Surge: Bill Ackman's personal investments propelled Pershing Square (PS) stock to a 36% increase on Friday, followed by a 6% rise in after-hours trading, despite still trading below the $50 listing price, indicating a recovery in market confidence towards his investments.
- Incentive Measures: The IPO featured a 'sweetener' where investors received an additional share of the management company for every five shares of the closed-end fund purchased, which, while still resulting in approximately a 3% loss for investors, aimed to attract more retail participation in the offering.
- Focus on Retail Investors: Ackman stated in an interview that PS's listing favored retail investors over institutional ones, and despite facing criticism for the fund's poor performance, he emphasized his commitment to supporting retail allocations, reflecting a strategic shift in market engagement.
- Optimistic Market Sentiment: Investor sentiment on Stocktwits was extremely bullish with high trading volumes, with some users even suggesting that PS could become the next 'Berkshire Hathaway', showcasing strong trust and expectations in Ackman's asset management capabilities.
See More
Strong IPO Performance from Biotech Firms
- Biotech Financing Success: Hemab Therapeutics raised $302 million, achieving an $849 million market cap, focusing on antibody therapies for blood coagulation disorders, with its lead candidate poised for Phase 3 trials, which is expected to significantly enhance the company's competitive edge in the biopharmaceutical market.
- Pulmonary Fibrosis Treatment Progress: Avalyn Pharma also completed its IPO with $300 million raised and an $813 million market cap, concentrating on inhaled antifibrotic therapies for rare respiratory diseases, with key clinical data expected in mid-2027, potentially driving long-term growth for the company.
- Neuropsychiatric Drug Development: Seaport Therapeutics successfully raised $255 million, reaching a $1.1 billion market cap, focusing on treatments for neuropsychiatric disorders, with its lead program GlyphAllo in Phase 2b trials, which could further solidify its market position if successful.
- Mining Company IPO Underperformance: Silver Bow Mining raised $60 million with a market cap of $368 million, focusing on various mineral resources but has yet to generate revenue, with a 7% drop in stock price on its first day, indicating market caution regarding its prospects.
See More
Ackman Blames Retail Investors for Pershing Square Stock Drop
- IPO Price Fluctuation: Pershing Square USA (PSUS) debuted at an IPO price of $50 per share but opened approximately 18% lower at $41 on Wednesday, indicating a lack of market confidence that could hinder future fundraising efforts.
- Retail Investor Behavior: Ackman criticized retail investors for overcommitting during the IPO, leading to forced sell-offs due to insufficient cash, which not only impacted stock prices but could also harm the company's long-term reputation.
- Institutional Investor Dominance: Ackman noted that over 80% of the capital came from institutional investors, highlighting that despite significant retail participation, institutional backing remains crucial, reflecting market confidence in the fund.
- Future Fund Plans: During a conference call in Montreal, Ackman indicated he might launch another fund within a year or even before the end of 2026, demonstrating his long-term optimism for the market despite current challenges.
See More
Bruce Herring Acquires 10,000 Shares in Pershing Square USA
- Share Acquisition Details: Bruce Herring's open-market purchase of 10,000 shares of Pershing Square USA, valued at approximately $434,000, reflects his confidence in the company's future prospects.
- Ownership Stake Analysis: Following this transaction, Herring's direct ownership stake in Pershing Square stands at 0.025%, indicating an enhanced influence within the company that could positively impact investor sentiment.
- Transaction Structure Transparency: The acquisition of all 10,000 shares was direct, with no involvement of trusts, family entities, or derivative instruments, ensuring compliance and transparency, which bolsters market trust in Herring.
- Market Performance and Investment Outlook: Despite PSUS's underwhelming debut performance with a closing price of $40.90, below its $50 IPO price, Herring's purchase may attract further investor interest, enhancing market recognition of the fund.
See More
Ackman's New Fund Debuts, Raising $5 Billion
- Successful Debut: Ackman's Pershing Square USA made a successful debut in the U.S. market, raising $5 billion and providing investors with a direct opportunity to invest in his stock picks, reflecting strong market confidence in his investment strategy.
- Return on Investment: With an annualized return of 16.2% since its inception in 2004, Ackman's investment approach makes the new fund an attractive option for investors, although they can also achieve returns by tracking his trades.
- Management Fees and Discounts: Shareholders investing in Pershing Square USA will incur a 2% management fee, and the fund may trade at a discount to its net asset value, adding uncertainty to investments, yet it still has the potential to outperform the market.
- Portfolio Transparency: Ackman intends to deploy the funds raised from the IPO within weeks and will file his first 13F report by mid-August, allowing investors to clearly understand his portfolio, which further enhances interest and trust in the fund.
See More
RPT-BUZZ-US STOCKS WEEKLY: UNDAUNTED
Market Overview: The U.S. stock market has shown resilience despite economic uncertainties, with investors remaining optimistic about future growth.
Sector Performance: Technology and healthcare sectors have outperformed others, driven by strong earnings reports and positive outlooks.
Economic Indicators: Recent economic data suggests a steady recovery, with improvements in employment rates and consumer spending.
Investor Sentiment: Overall investor sentiment remains bullish, with many looking for opportunities in undervalued stocks amidst market fluctuations.
See More
Bill Ackman's Investments Boost PS Stock Price
- Stock Price Surge: Bill Ackman's personal investments propelled Pershing Square (PS) stock to a 36% increase on Friday, followed by a 6% rise in after-hours trading, despite still trading below the $50 listing price, indicating a recovery in market confidence towards his investments.
- Incentive Measures: The IPO featured a 'sweetener' where investors received an additional share of the management company for every five shares of the closed-end fund purchased, which, while still resulting in approximately a 3% loss for investors, aimed to attract more retail participation in the offering.
- Focus on Retail Investors: Ackman stated in an interview that PS's listing favored retail investors over institutional ones, and despite facing criticism for the fund's poor performance, he emphasized his commitment to supporting retail allocations, reflecting a strategic shift in market engagement.
- Optimistic Market Sentiment: Investor sentiment on Stocktwits was extremely bullish with high trading volumes, with some users even suggesting that PS could become the next 'Berkshire Hathaway', showcasing strong trust and expectations in Ackman's asset management capabilities.
See More
Strong IPO Performance from Biotech Firms
- Biotech Financing Success: Hemab Therapeutics raised $302 million, achieving an $849 million market cap, focusing on antibody therapies for blood coagulation disorders, with its lead candidate poised for Phase 3 trials, which is expected to significantly enhance the company's competitive edge in the biopharmaceutical market.
- Pulmonary Fibrosis Treatment Progress: Avalyn Pharma also completed its IPO with $300 million raised and an $813 million market cap, concentrating on inhaled antifibrotic therapies for rare respiratory diseases, with key clinical data expected in mid-2027, potentially driving long-term growth for the company.
- Neuropsychiatric Drug Development: Seaport Therapeutics successfully raised $255 million, reaching a $1.1 billion market cap, focusing on treatments for neuropsychiatric disorders, with its lead program GlyphAllo in Phase 2b trials, which could further solidify its market position if successful.
- Mining Company IPO Underperformance: Silver Bow Mining raised $60 million with a market cap of $368 million, focusing on various mineral resources but has yet to generate revenue, with a 7% drop in stock price on its first day, indicating market caution regarding its prospects.
See More
Ackman Blames Retail Investors for Pershing Square Stock Drop
- IPO Price Fluctuation: Pershing Square USA (PSUS) debuted at an IPO price of $50 per share but opened approximately 18% lower at $41 on Wednesday, indicating a lack of market confidence that could hinder future fundraising efforts.
- Retail Investor Behavior: Ackman criticized retail investors for overcommitting during the IPO, leading to forced sell-offs due to insufficient cash, which not only impacted stock prices but could also harm the company's long-term reputation.
- Institutional Investor Dominance: Ackman noted that over 80% of the capital came from institutional investors, highlighting that despite significant retail participation, institutional backing remains crucial, reflecting market confidence in the fund.
- Future Fund Plans: During a conference call in Montreal, Ackman indicated he might launch another fund within a year or even before the end of 2026, demonstrating his long-term optimism for the market despite current challenges.
See More
